Cidara Provides Corporate Update And Reports Second Quarter 2017 Financial Results

Published: Aug 10, 2017

SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and provided an update on its corporate activities and product pipeline.

“We began the second quarter of 2017 by welcoming the financial community to our inaugural Investor Day, in New York, where we described plans for our CD101 and Cloudbreak™ programs and heard presentations from key opinion leaders,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Back to news